Neos Therapeutics to Host Third Quarter 2017 Financial Results Conference Call on November 8, 2017
November 02 2017 - 8:00AM
Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company
focused on developing, manufacturing and commercializing innovative
extended-release (XR) products using its proprietary
modified-release drug delivery and orally disintegrating tablet
(ODT) technology platforms, today announced that it will report its
third quarter 2017 financial results prior to the opening of U.S.
financial markets on Wednesday, November 8, 2017. Neos management
will host a conference call and live audio webcast to discuss these
results and provide a company update at 8:30 a.m. ET that same day.
The live call may be accessed by dialing (877)
388-8985 for domestic calls, or +1 (562) 912-2654 for international
callers, and referencing conference ID number 97314658. A live
audio webcast for the conference call will be available on the
Investor Relations page of the company’s website at
http://investors.neostx.com/.
About Neos Therapeutics
Neos Therapeutics, Inc. (NASDAQ:NEOS) is a
pharmaceutical company focused on developing, manufacturing and
commercializing products utilizing its proprietary modified-release
drug delivery technology platforms. Adzenys XR-ODT® (amphetamine)
extended-release orally disintegrating tablets (see Full
Prescribing Information, including Boxed WARNING), Cotempla XR-ODT™
(methylphenidate) extended-release orally disintegrating tablets
(see Full Prescribing Information, including Boxed WARNING), and
Adzenys-ER™ (amphetamine) extended-release oral suspension (see
Full Prescribing Information, including Boxed WARNING), all for the
treatment of ADHD, are the first three approved products using the
Company’s extended-release technology platform. In addition,
Neos manufactures and markets its generic version of the branded
product Tussionex®1, an extended-release oral suspension of
hydrocodone and chlorpheniramine for the relief of cough and upper
respiratory symptoms of a cold (see Full Prescribing Information,
including Boxed WARNING). Additional information about Neos is
available at www.neostx.com.
1Tussionex® is a registered trademark of
the UCB Group of Companies.
Contacts:
Richard Eisenstadt
Chief
Financial Officer
Neos Therapeutics
(972) 408-1389
reisenstadt@neostx.com
Sarah McCabe Senior Vice President
Stern Investor Relations, Inc.(212)
362-1200 sarah@sternir.com
Neos Therapeutics (NASDAQ:NEOS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Neos Therapeutics (NASDAQ:NEOS)
Historical Stock Chart
From Apr 2023 to Apr 2024